Lite Paper: Real-World PD-L1 Testing Data Provides Insight into the Evolving Immuno-oncology Landscape

Case Study: How Pharma Uses NeoGenomics Real-World Oncology Data to Accelerate Biomarker Adoption and Commercial Launch

The Breakroom Video Series

NeoGenomics is proud to share the Breakroom video series.

Read More

Taking Spatial Toward the Clinic: DeciBio’s Q&A with Sandy Au of NeoGenomics

Blog originally posted on Decibio Insights here.

Read More

Is IHC going to exhaust our archival blocks the way single gene testing used to?

Over the past year we have seen unprecedented demand for IHC assay development services with the goal of creating a prototype CDx assay.

Read More
Written By:
Scott Reid

NeoGenomics announces speaker program, ‘Minimal Residual Disease in Colorectal Cancer’

NeoGenomics is pleased to announce a speaker program titled ‘Minimal Residual Disease in Colorectal Cancer.’

Read More

IVDR at NeoGenomics

With the recent application of IVDR on May 26, 2022, there are new regulatory standards that oversee the sales and use of IVDs for the EU.

Read More
Written By:
James Yen

NeoGenomics Hurricane Ian Emergency Response

as of 6:00pm ET


Dear Valued Client,

Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients